Format

Send to

Choose Destination
Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Author information

1
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
2
Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
3
Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
4
Department of Clinical Pharmacy, Utrecht University Medical Center, Utrecht, The Netherlands.

Abstract

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

PMID:
28699160
PMCID:
PMC5656880
DOI:
10.1002/cpt.787
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center